Rickettsial agents are some of the most lethal pathogens known to man. Among them, Rickettsia prowazekii is a select agent with potential use for bioterrorism; yet, there is no anti-Rickettsia
vaccine commercially available. Owing to the obligate intracellular lifestyle of rickettsiae, CD8(+) T cells are indispensable for protective cellular immunity. Furthermore, T cells can mediate cross-protective immunity between different pathogenic Rickettsia, a finding consistent with the remarkable similarity among rickettsial genomes. However, Rickettsia T cell
antigens remain unidentified. In the present study, we report an algorithm that allowed us to identify and validate four novel R. prowazekii
vaccine antigen candidates recognized by CD8(+) T cells from a set of twelve in silico-defined
protein targets. Our results highlight the importance of combining
proteasome-processing as well as MHC class-I-binding predictions. The novel rickettsial
vaccine candidate
antigens, RP778, RP739, RP598, and RP403, protected mice against a lethal challenge with Rickettsia typhi, which is indicative of cross-protective immunity within the
typhus group rickettsiae. Together, our findings validate a reverse vaccinology approach as a viable strategy to identify protective rickettsial
antigens and highlight the feasibility of a
subunit vaccine that triggers T-cell-mediated cross-protection among diverse rickettsiae.